| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sirolimus | 11 | 2015 | 839 | 0.970 |
Why?
|
| TOR Serine-Threonine Kinases | 13 | 2017 | 1575 | 0.750 |
Why?
|
| Proto-Oncogene Proteins c-akt | 9 | 2019 | 2085 | 0.630 |
Why?
|
| Breast Neoplasms | 19 | 2023 | 16251 | 0.520 |
Why?
|
| Phosphatidylinositol 3-Kinases | 7 | 2014 | 1719 | 0.490 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2021 | 9096 | 0.450 |
Why?
|
| Proteomics | 1 | 2021 | 1434 | 0.440 |
Why?
|
| Transcriptome | 1 | 2021 | 1948 | 0.400 |
Why?
|
| Genomics | 2 | 2021 | 2824 | 0.370 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 4 | 2021 | 531 | 0.350 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2021 | 1384 | 0.340 |
Why?
|
| Signal Transduction | 12 | 2014 | 12212 | 0.330 |
Why?
|
| Protein Kinases | 4 | 2009 | 919 | 0.310 |
Why?
|
| Antigens, Neoplasm | 2 | 2006 | 1591 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2022 | 529 | 0.300 |
Why?
|
| PTEN Phosphohydrolase | 4 | 2021 | 1014 | 0.290 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 3 | 2019 | 153 | 0.280 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2009 | 557 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2021 | 5417 | 0.250 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2024 | 3931 | 0.230 |
Why?
|
| Barium Sulfate | 1 | 2002 | 41 | 0.210 |
Why?
|
| Colonic Diseases, Functional | 1 | 2002 | 19 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2021 | 4964 | 0.210 |
Why?
|
| Enema | 1 | 2002 | 50 | 0.210 |
Why?
|
| Mice, Nude | 9 | 2022 | 4359 | 0.210 |
Why?
|
| Stearoyl-CoA Desaturase | 2 | 2012 | 20 | 0.200 |
Why?
|
| Cell Proliferation | 10 | 2021 | 7301 | 0.200 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 5183 | 0.190 |
Why?
|
| Peritoneal Neoplasms | 1 | 2008 | 857 | 0.190 |
Why?
|
| Oxadiazoles | 1 | 2021 | 60 | 0.190 |
Why?
|
| Esophageal Neoplasms | 2 | 2006 | 3239 | 0.190 |
Why?
|
| Neurofibromin 1 | 1 | 2021 | 84 | 0.180 |
Why?
|
| B7 Antigens | 1 | 2021 | 84 | 0.180 |
Why?
|
| Acute-Phase Reaction | 1 | 2000 | 24 | 0.180 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 276 | 0.180 |
Why?
|
| Cation Transport Proteins | 1 | 2021 | 172 | 0.170 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 272 | 0.170 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2013 | 744 | 0.170 |
Why?
|
| Hernia, Inguinal | 1 | 2000 | 51 | 0.170 |
Why?
|
| Cell Line, Tumor | 14 | 2021 | 14882 | 0.170 |
Why?
|
| Antineoplastic Agents | 5 | 2021 | 14649 | 0.160 |
Why?
|
| Anilides | 1 | 2021 | 295 | 0.160 |
Why?
|
| Carrier Proteins | 1 | 2007 | 2138 | 0.160 |
Why?
|
| Colon | 1 | 2002 | 691 | 0.160 |
Why?
|
| Metabolome | 1 | 2021 | 356 | 0.160 |
Why?
|
| Benzimidazoles | 1 | 2022 | 441 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 3671 | 0.160 |
Why?
|
| RNA, Neoplasm | 1 | 2021 | 810 | 0.150 |
Why?
|
| Female | 32 | 2023 | 149201 | 0.150 |
Why?
|
| Cell Cycle Proteins | 3 | 2021 | 2127 | 0.150 |
Why?
|
| Phosphorylation | 7 | 2015 | 4982 | 0.150 |
Why?
|
| Teaching | 1 | 1999 | 252 | 0.150 |
Why?
|
| Accidents, Aviation | 1 | 1997 | 7 | 0.150 |
Why?
|
| Traumatology | 1 | 1997 | 26 | 0.150 |
Why?
|
| Receptor, ErbB-2 | 3 | 2024 | 2649 | 0.140 |
Why?
|
| Disaster Planning | 1 | 1997 | 70 | 0.140 |
Why?
|
| Multiple Trauma | 1 | 1997 | 76 | 0.140 |
Why?
|
| Humans | 40 | 2024 | 271887 | 0.140 |
Why?
|
| Evolution, Molecular | 1 | 2021 | 869 | 0.140 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 1997 | 76 | 0.140 |
Why?
|
| Neoplasms | 5 | 2015 | 15907 | 0.140 |
Why?
|
| Cytoplasm | 2 | 2009 | 718 | 0.130 |
Why?
|
| Contrast Media | 1 | 2002 | 1506 | 0.130 |
Why?
|
| Piperidines | 1 | 2021 | 1091 | 0.130 |
Why?
|
| Respiratory Function Tests | 1 | 1997 | 355 | 0.130 |
Why?
|
| Hydrazines | 1 | 2017 | 214 | 0.130 |
Why?
|
| Blotting, Western | 5 | 2011 | 3644 | 0.130 |
Why?
|
| Phthalazines | 1 | 2017 | 263 | 0.130 |
Why?
|
| Mutation | 5 | 2021 | 15951 | 0.130 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 379 | 0.130 |
Why?
|
| DNA, Neoplasm | 1 | 2021 | 1972 | 0.130 |
Why?
|
| Mice | 14 | 2024 | 36017 | 0.130 |
Why?
|
| Animals | 18 | 2024 | 62766 | 0.120 |
Why?
|
| Developing Countries | 1 | 1997 | 342 | 0.120 |
Why?
|
| Interleukin-10 | 1 | 1997 | 482 | 0.120 |
Why?
|
| Paclitaxel | 4 | 2015 | 2102 | 0.120 |
Why?
|
| Pancreatitis | 1 | 1997 | 293 | 0.120 |
Why?
|
| Benzoxazoles | 1 | 2014 | 40 | 0.120 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 522 | 0.120 |
Why?
|
| Pyridines | 1 | 2021 | 1311 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2022 | 16625 | 0.110 |
Why?
|
| Membrane Proteins | 1 | 2004 | 2972 | 0.110 |
Why?
|
| Heterografts | 1 | 2015 | 745 | 0.110 |
Why?
|
| Triazoles | 1 | 2017 | 629 | 0.110 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 64 | 0.100 |
Why?
|
| Emergency Medical Services | 1 | 1997 | 465 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 2622 | 0.100 |
Why?
|
| Receptors, Estrogen | 3 | 2015 | 2268 | 0.090 |
Why?
|
| Biomarkers, Tumor | 4 | 2021 | 10752 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 1884 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 4816 | 0.090 |
Why?
|
| Protein Biosynthesis | 2 | 2012 | 1035 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2021 | 5103 | 0.090 |
Why?
|
| Proteome | 1 | 2014 | 573 | 0.090 |
Why?
|
| MCF-7 Cells | 3 | 2017 | 554 | 0.090 |
Why?
|
| Receptors, Progesterone | 2 | 2012 | 1649 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 1004 | 0.080 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2009 | 233 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 3362 | 0.080 |
Why?
|
| Leucine | 1 | 2011 | 381 | 0.080 |
Why?
|
| Y-Box-Binding Protein 1 | 1 | 2009 | 44 | 0.080 |
Why?
|
| Adult | 12 | 2019 | 81935 | 0.080 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2009 | 123 | 0.080 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2009 | 135 | 0.080 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2008 | 95 | 0.080 |
Why?
|
| Internship and Residency | 1 | 1999 | 1441 | 0.080 |
Why?
|
| Immunohistochemistry | 3 | 2019 | 7829 | 0.070 |
Why?
|
| Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2007 | 31 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2023 | 3664 | 0.070 |
Why?
|
| Transfection | 2 | 2015 | 3166 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 3 | 2022 | 2470 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2007 | 611 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2022 | 384 | 0.070 |
Why?
|
| Aged | 10 | 2019 | 73478 | 0.070 |
Why?
|
| B7-H1 Antigen | 1 | 2014 | 1073 | 0.070 |
Why?
|
| Apoptosis | 5 | 2021 | 7838 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2009 | 663 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 2 | 2014 | 2397 | 0.070 |
Why?
|
| Middle Aged | 11 | 2019 | 90414 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2009 | 9316 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 3703 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 1209 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 703 | 0.070 |
Why?
|
| Carcinoid Tumor | 1 | 2008 | 282 | 0.060 |
Why?
|
| Phosphoproteins | 2 | 2008 | 1228 | 0.060 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2012 | 741 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 10368 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 12012 | 0.060 |
Why?
|
| RNA, Small Interfering | 2 | 2010 | 2218 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2008 | 1478 | 0.060 |
Why?
|
| Tumor Burden | 3 | 2015 | 2035 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 2 | 2015 | 5212 | 0.060 |
Why?
|
| RNA | 1 | 2009 | 1071 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2021 | 1364 | 0.060 |
Why?
|
| Prognosis | 3 | 2021 | 22538 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2023 | 7473 | 0.060 |
Why?
|
| Time Factors | 3 | 2015 | 13128 | 0.060 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2023 | 100 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2004 | 386 | 0.050 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2023 | 156 | 0.050 |
Why?
|
| Spasm | 1 | 2002 | 59 | 0.050 |
Why?
|
| Appendix | 1 | 2002 | 45 | 0.050 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2023 | 189 | 0.050 |
Why?
|
| Ileum | 1 | 2002 | 175 | 0.050 |
Why?
|
| Neuroendocrine Tumors | 1 | 2008 | 653 | 0.050 |
Why?
|
| HCT116 Cells | 1 | 2022 | 354 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 3854 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 5110 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 2 | 2015 | 1323 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2015 | 31061 | 0.050 |
Why?
|
| Everolimus | 2 | 2014 | 438 | 0.050 |
Why?
|
| Mathematical Computing | 1 | 1999 | 23 | 0.040 |
Why?
|
| Testis | 1 | 2004 | 753 | 0.040 |
Why?
|
| Transplantation, Heterologous | 2 | 2012 | 1085 | 0.040 |
Why?
|
| Pyrroles | 1 | 2023 | 592 | 0.040 |
Why?
|
| Male | 8 | 2015 | 128993 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 5804 | 0.040 |
Why?
|
| Professional Competence | 1 | 1999 | 134 | 0.040 |
Why?
|
| Mitosis | 1 | 2021 | 692 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2004 | 755 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 3537 | 0.040 |
Why?
|
| Acrylonitrile | 1 | 2017 | 9 | 0.040 |
Why?
|
| Radiography | 1 | 2002 | 1994 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2022 | 886 | 0.040 |
Why?
|
| Turkey | 1 | 1997 | 66 | 0.040 |
Why?
|
| Rural Health | 1 | 1997 | 55 | 0.040 |
Why?
|
| Ketones | 1 | 2017 | 59 | 0.040 |
Why?
|
| Furans | 1 | 2017 | 103 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2019 | 355 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2000 | 565 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2017 | 206 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 5329 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 2363 | 0.030 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 13999 | 0.030 |
Why?
|
| Health Services Research | 1 | 1997 | 242 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2015 | 122 | 0.030 |
Why?
|
| Triage | 1 | 1997 | 258 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2000 | 1060 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2009 | 1831 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2023 | 1544 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2015 | 167 | 0.030 |
Why?
|
| Allosteric Regulation | 1 | 2014 | 73 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2014 | 69 | 0.030 |
Why?
|
| Epirubicin | 1 | 2014 | 159 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2014 | 306 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2015 | 317 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2014 | 276 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 472 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2017 | 514 | 0.030 |
Why?
|
| Pyridones | 1 | 2015 | 362 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2015 | 271 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 3395 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 102 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2014 | 389 | 0.030 |
Why?
|
| Drug Design | 1 | 2014 | 378 | 0.030 |
Why?
|
| Cadherins | 1 | 2015 | 675 | 0.030 |
Why?
|
| Research Design | 1 | 1999 | 1577 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 10257 | 0.030 |
Why?
|
| Models, Biological | 2 | 2012 | 3221 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2015 | 350 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2006 | 3542 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1102 | 0.020 |
Why?
|
| Acute Disease | 1 | 1997 | 2509 | 0.020 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2014 | 238 | 0.020 |
Why?
|
| Lung Diseases | 1 | 1997 | 757 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 621 | 0.020 |
Why?
|
| RNA Interference | 1 | 2015 | 1397 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1084 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2019 | 33905 | 0.020 |
Why?
|
| Neutropenia | 1 | 2015 | 1001 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2014 | 751 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2015 | 1435 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2012 | 505 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2017 | 3146 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 1132 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 2356 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2010 | 735 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2012 | 1741 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2010 | 6485 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2014 | 1988 | 0.020 |
Why?
|
| Fatigue | 1 | 2015 | 1280 | 0.020 |
Why?
|
| Nucleotides | 1 | 2009 | 175 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 1513 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 1827 | 0.020 |
Why?
|
| Biomarkers | 1 | 2019 | 5097 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 3978 | 0.020 |
Why?
|
| Octreotide | 1 | 2008 | 132 | 0.020 |
Why?
|
| Child | 2 | 2000 | 30564 | 0.020 |
Why?
|
| Transgenes | 1 | 2009 | 589 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 3243 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 4346 | 0.020 |
Why?
|
| Adolescent | 2 | 2013 | 32738 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4391 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 3512 | 0.010 |
Why?
|
| Base Sequence | 1 | 2010 | 5501 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6273 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 2494 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2015 | 2909 | 0.010 |
Why?
|
| Protein Binding | 1 | 2009 | 3527 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2015 | 5504 | 0.010 |
Why?
|
| DNA | 1 | 2009 | 3089 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 5783 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 3471 | 0.010 |
Why?
|
| Young Adult | 1 | 2013 | 22159 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 12544 | 0.010 |
Why?
|